Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals ( ($AMRX) ) has shared an update. On August 3, 2026, Amneal Pharmaceuticals LLC and certain subsidiaries executed Amendment ...

Amneal Pharmaceuticals Reprices Term Loans to Reduce Interest

Amneal Pharmaceuticals ( ($AMRX) ) has shared an update. On July 31, 2026, Amneal Pharmaceuticals held a special meeting of stockholders at which h...

Amneal Stockholders Approve Kashiv BioSciences Acquisition Plans

Goldman Sachs analyst Salveen Richter maintained a Buy rating on Amneal Pharmaceuticals today and set a price target of $19.00. According to TipRan...

Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALN...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALNY) and Biogen (BIIB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Eras...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMRX	$18.20	+0.28%	667.07K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMRX	$18.20	+0.3%	667.07K
3
4
5
6

AMRX

Get Amneal Pharmaceuticals, Inc. Data in Excel

Get Amneal Pharmaceuticals, Inc. Data in Excel